Brought to you by 
Two months after postponing offer, Celladon nets $44.3mm in refiled Nasdaq IPO
27 May 2014
Executive Summary
Celladon Corp. (calcium dysregulation therapeutics) netted $44.3mm in its IPO, selling 6.3mm shares (including the overallotmnet) at $8, a steep decline from its proposed $14-16 range announced in November 2013, shortly before it postponed the offer (originally filed in October 2013) citing poor market conditions.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Two months after postponing offer, Celladon nets $44.3mm in refiled Nasdaq IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice